Right ventricular dysfunction and tricuspid regurgitation in functional mitral regurgitation

Vien T. Truong1,2*, Tam N.M. Ngo1,3†, Jan Mazur4, Hoai T.M. Nguyen3, Thuy T.M. Pham5, Cassady Palmer1, Khanh N.P. Pham6, Hoang T. Phan3,7, Kwan S. Lee8, Marwin Bannehr9, Christian Butter9, Takayuki Gyoten10 and Eugene S. Chung1

1 The Christ Hospital Health Network, 2139 Auburn Ave, Cincinnati, OH 45219, USA; 2 The Sue and Bill Butler Research Fellow, The Linder Research Center, Cincinnati, OH, USA; 3 Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam; 4 The Ohio State University, Columbus, OH, USA; 5 Heart Center, Tam Anh General Hospital, Ho Chi Minh City, Vietnam; 6 115 People’s Hospital, Ho Chi Minh City, Vietnam; 7 Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia; 8 Sir Ver Heart Center, Department of Medicine, University of Arizona College of Medicine, Tucson, AZ, USA; 9 Heart Center Brandenburg in Bernau/Berlin, Department of Cardiology & Brandenburg, Medical School Theodor Fontane, Neuruppin, Germany; and 10 Cardiac Surgery, Sana Herzcentrum Cottbus, Cottbus, Germany

Abstract

Aim The objective of this study was to investigate the prognostic importance of right ventricular dysfunction (RVD) and tricuspid regurgitation (TR) in patients with moderate–severe functional mitral regurgitation (FMR) receiving MitraClip procedure. RVD and TR grade are associated with cardiovascular mortality in the general population and other cardiovascular diseases. However, there are limited data from observational studies on the prognostic significance of RVD and TR in FMR receiving MitraClip procedure.

Methods and results A systemic review and meta-analysis were performed using MEDLINE, Scopus, and Embase to assess the prognostic value of RVD and TR grade for mortality in patients with functional mitral regurgitation (FMR) receiving MitraClip procedure. Hazard ratios were extracted from multivariate models reporting on the association of RVD and TR with mortality and described as pooled estimates with 95% confidence intervals. A total of eight non-randomized studies met the inclusion criteria with seven studies having at least 12 months follow-up with a mean follow-up of 20.9 months. Among the aforementioned studies, a total of 1112 patients (71.5% being male) were eligible for being included in our meta-analysis with an overall mortality rate of 28.4% (n = 316). Of the enrolled patients, RVD was present in 46.1% and moderate–severe TR in 29.2%. RVD was significantly associated with mortality compared to normal RV function (HR, 1.79, 95% CI, 1.39–2.31, P < 0.001, I² = 0). Patients with moderate–severe TR showed increased risk of mortality compared with those in the none-mild TR group (HR, 1.61. 95% CI, 1.11–2.33, P = 0.01, I² = 14).

Conclusions This meta-analysis demonstrates the prognostic importance of RVD and TR grade in predicting all-cause mortality in patients with significant FMR. RV function and TR parameters may therefore be useful in the risk stratification of patients with significant FMR undergoing MitraClip procedure.

Keywords Right ventricular dysfunction; Tricuspid regurgitation; Functional mitral regurgitation; MitraClip procedure; Mortality; Meta-analysis

Received: 5 February 2021; Revised: 6 July 2021; Accepted: 28 July 2021
*Correspondence to: Vien T. Truong, The Christ Hospital Health Network, FACC, 2139 Auburn Ave, Cincinnati, OH 45219, USA. Phone: 513-206-1120. Email: thanhvientruong1988@gmail.com
†These authors contributed equally to this work.

Introduction

Functional mitral regurgitation (FMR) is a common clinical entity in patients with primary left ventricular (LV) dysfunction with normal mitral valve anatomy. FMR has been associated with adverse prognosis independent of both LV ejection fraction (LVEF) and other clinical markers of heart failure.1–3 Percutaneous mitral valve repair using the MitraClip device has been proposed to correct FMR. The COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation) trial confers a survival benefit compared with
optimal medical therapy. On the contrary, the MITRA-FR (Multicentre Study of Percutaneous Mitral Valve Repair MitraClip Device in Patients With Severe Secondary Mitral Regurgitation) trial did not demonstrate a survival benefit. The difference in the results of two landmark randomized trials have underscored the importance of correct patient selection for this intervention. Noticeably, compared with patients in the MITRA-FR trial, those enrolled in the COAPT trial had less advanced stage of the LV disease with smaller LV end-diastolic volume index (COAPT: 101 ± 34 mL/m² vs. MITRA-FR: 135 ± 35 mL/m²) and greater LVEF (COAPT: 20–50% vs. MITRA-FR 15–40%).

In light of the available evidence, identifying patients who will benefit from the intervention and searching for prognostic predictors are of utmost importance. Right ventricular dysfunction (RVD) and tricuspid regurgitation (TR) grade have been demonstrated to be associated with increased cardiovascular mortality in the general population, primary MR, and other cardiovascular and respiratory diseases. Recently, Nakasu et al. showed that RVD is a significant predictor of sudden cardiac death (SCD) irrespective of left ventricular ejection fraction. However, there are limited data from observational studies on the prognostic significance of RVD and TR in FMR. Importantly, the two landmark randomized trials did not account the importance of RVD into their protocols. The ongoing clinical trial ‘A Clinical Evaluation of the Safety and Effectiveness of the MitraClip System in the Treatment of Clinically Significant Functional Mitral Regurgitation’ (Reshape-HF2) has not mentioned RV function in their inclusion and exclusion criteria.

The objective of this study was to investigate the prognostic importance of RVD, and TR in patients with moderate–severe FMR undergoing MitraClip procedure by performing a systematic review of the literature and meta-analysis.

Methods

Search strategy

We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines when performing our systematic review and meta-analysis. We searched PubMed, Scopus, and Embase databases using English-language references from inception through April 2020 using the search term ‘TAPSE’ OR ‘Tricuspid annular plane systolic excursion’ OR ‘right ventricular dysfunction’ OR ‘right ventricular function’ OR ‘right ventricle’ OR ‘right ventricular’ OR ‘tricuspid regurgitation’ OR ‘tricuspid valve regurgitation’ OR ‘pulmonary hypertension’ AND (‘functional’ OR ‘secondary’) AND (‘mitral valve regurgitation’ OR ‘mitral valve insufficiency’ OR ‘mitral regurgitation’ OR ‘mitral insufficiency’). Additional strategies involved reference searches to ensure the identification of all relevant studies pertinent to the topic. The search was limited to human studies published in English. Abstracts without complete published articles, review articles, editorial comments, and letters to the editor were excluded.

Study selection

The PICO (the patient, population or problem, intervention, comparison, outcomes) framework was used as a tool to outline the components of the research questions (Table 1). Studies were included if the articles met the following criteria: (i) reporting an association between RVD or tricuspid regurgitation and an outcome, either mortality or heart failure (HF) related hospitalization among patients with FMR; (ii) having at least 6 month follow-up; (iii) controlling for other important covariates in multivariable survival analysis; (iv) having low risk of bias assessed by the Newcastle-Ottawa scale (see Quality assessment section for more details). In the studies that reported an association of RVD or TR with outcomes among those with FMR mixed with primary MR, we contacted the authors of the studies for accessing data related to FMR. Paediatric populations were excluded to minimize heterogeneity between studies.

Data extraction

Each eligible article meeting the inclusion criteria was reviewed by two independent reviewers (T. N and V. T. or T. P.). Disagreements were resolved by a consensus with a
third investigator (K. P. or T. N.). The following data were extracted and entered into an electronic database: (i) study: first and last authors, year of publication; (ii) socio-demographics: number of subjects, age, and gender; (iii) clinical factors: proportion of ischemic cardiomyopathy, NYHA, MitraClip procedure; (iv) echocardiographic parameters: LV end-diastolic diameter (LVEDD), LV end-systolic diameter (LVESD), LV end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), LVEDV index, LVESV index, and LV ejection fraction (EF), systolic pulmonary artery pressure (SPAP), TAPSE, TR, and MR. RVD was defined as a TAPSE ≤ 16 mm or tissue Doppler-derived tricuspid lateral annular systolic velocity (S/VTDI) < 10 cm/s.20 The severity of tricuspid regurgitation (TR) assessed in line with recommendations and TR was graded as none, mild, moderate, moderate, or severe; and (v) clinical outcomes: follow-up (months), mortality, HF-related hospitalization. In situations in which we believed that multiple articles were published using the same dataset, the study with the largest sample size was included in our meta-analysis.

Analysis of outcomes

Mortality and HF-related hospitalizations were the major outcomes of interest. HF-related hospitalization was defined as new-onset or worsening signs and symptoms of HF that required urgent therapy and resulted in hospitalization. Analysis of an outcome was pooled if at least two studies reported that outcome.

Quality assessment

Quality assessment of the studies was performed using the Newcastle–Ottawa scale, one of the most used tool for evaluating quality in meta-analyses of observational studies.21 The Newcastle–Ottawa scale, including nine items, appraises methodological quality in three domains: selection, comparability, and outcome with a maximum of 9 points. Based on the quality assessment tool, studies were classified as having high-risk (1–3 points), intermediate-risk (4–5 points), or low-risk of bias (6–9 points). Two reviewers (V. T. and T. P.) independently performed the quality assessment across all potentially eligible studies for this systematic review and meta-analysis. Only studies with low risk of bias (6–9 points) were included in our meta-analysis.

Statistical analysis

All statistical analyses were performed using the Comprehensive Meta-Analysis (version 3.3). For the incidence rate data, we calculated the hazard ratio (HR) with 95% CI as reported in the individual studies. Study-specific data were then combined to create pooled estimates using DerSimonian–Laird random-effects models.22 Heterogeneity among studies was assessed using Cochrane’s Q test with P value of <0.1 considered as statistically significant heterogeneity and I² statistic. I² statistic was categorized as low (<25%), moderate (25% to 75%), or high (>75%) levels of heterogeneity.23 Publication bias was assessed using visual funnel plot and the Egger’s and Begg’s tests, with significant bias defined as a P value <0.1. The ‘trim and fill’ method was used to examine whether hypothetical missing studies substantially changed our estimates.24

The additional sensitivity analyses were planned: the first including studies using TAPSE to define RVD, the second using the ‘leave-one-out-at-a-time’ approach, where one study is excluded at a time and the impact of removing each of the studies is on the pooled estimates and the between-study heterogeneity.25

Results

Study selection

Figure 1 shows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flowchart of our study. The search identified 446 titles on Medline, 1137 on EMBASE, 436 on Scopus. After excluding duplicate and triplicate articles (n = 846), there were 1173 articles screened for relevance. We further excluded articles unrelated to the topic (n = 416) or abstracts without text (n = 528), reviews (n = 92), and articles not in humans (n = 11). Searching the bibliographies did not reveal any additional results. No ongoing studies were found in the clinical trials registries. One hundred twenty-six full-text studies were assessed for eligibility. After removing further 117 studies due to aforementioned reasons or those with repeated datasets, eight datasets were included in our meta-analysis.18,19,26–31

Association of ventricular dysfunction dysfunction and tricuspid regurgitation with mortality in functional mitral regurgitation

The baseline characteristics of study participants and echocardiographic data were shown in Tables 2 and 3. Among the eight studies eligible to be included in our meta-analysis, there were a total of 1112 patients (71.5% being male) with an overall mortality rate of 28.4% (n = 316). Study-specific follow-up duration was reported in Table 2 with seven studies having at least 12 months follow-up with a mean follow-up of 20.9 months. There were 85% of patients who presented with NYHA class III–IV. The pooled mean LVEF among all participants was 29.3 ± 8.8%.
Of the enrolled patients, RVD was present in 46.1% and moderate–severe TR in 29.2%. Our meta-analysis showed that patients with RVD was significantly associated with mortality compared with normal RV function (HR, 1.79, 95% CI, 1.39–2.31, \(P < 0.001\)) (Figure 2) with low heterogeneity between studies (\(Q = 4.66, P = 0.32, \text{and } \chi^2 = 14\%\)).

### Sensitivity analysis

The first subgroup analysis was undertaken among the studies that used TAPSE to assess the RV function. Again, RVD that was
Table 3  Echocardiographic characteristics of included observational studies

| Author             | LVEDD (cm) | LVESD (cm) | LVEDV (ml) | LVESV (ml) | LVEF (%) | EROA (cm²) | TAPSE (mm) | SPAP (mmHg) | Moderate−Severe TR (%) | Severe TR (% | Moderate−Severe TR (%) | Severe TR (%) | NR (%) |
|--------------------|------------|------------|------------|------------|----------|------------|------------|-------------|------------------------|--------------|------------------------|--------------|--------|
| Gyoten et al.      | 73 ± 6.4   | 66 ± 7.1   | 242 ± 69   | 182 ± 64   | 60 ± 6   | 65 ± 16    | NR         | NR          | 54 ± 15                 | 14 ± 4.6     | 50 ± 15                 | 14 ± 4.6     | NR     |
| Bannehr et al.     | 62.9 ± 8.5 | 52.1 ± 10.4| NR         | NR         | NR       | 29.6 ± 11.1| 0.29 ± 0.26| 40.7 ± 12.4| 16.9 ± 4.8              | 57 (52.8)    | 51 (47.2)               | 52 (48.1)    | NR     |
| Osteresch et al.   | 60 ± 9     | 55 ± 9     | NR         | NR         | NR       | 32 ± 7     | 0.38 ± 0    | 49 ± 12      | 18 ± 4                 | 58 (44.6)    | 15 (11.5)               | 106 (81.5)   | NR     |
| Godino et al.      | 66.8 ± 9.2 | 56.1 ± 10.2| 210 ± 78   | 147 ± 69   | 63 ± 74  | 30 ± 10    | NR         | NR          | 50 ± 16                 | 22 ± 4       | 75 (64.1)               | 78 (72)      | NR     |
| Kaneko et al.      | 67 ± 9.4   | 58 ± 9.7   | NR         | NR         | NR       | 24.9 ± 7.35| NR         | NR          | 16.5 ± 2.6              | 41 (35.0)    | 25 (21.4)               | 47 (30.2)    | NR     |
| Hahn and Stone et al | 79 ± 35b  | 31 ± 34    | 31 ± 9     | NR         | 50 ± 13  | NR         | NR         | NR          | 84 (49.7)               | 78 (72)      | NR         | 154 (51.0)  | NR     |
| Giannini et al.    | 7 ± 6 b    | 31 ± 6 b   | 111 (90–136) | 79 ± 35b  | 31 ± 9   | NR         | 3.4 ± 0.3  | 44.0 ± 13.4| NR                     | NR          | NR         | 154 (51.0)  | NR     |
| Ohno et al.        | 60.2 ± 7.0 | 50.3 ± 0.9 | 19.0 ± 1.7 | 16.5 ± 2.6 | 41 (35.0) | 25 (21.4)  | NR         | NR          | 84 (49.7)               | 78 (72)      | NR         | 154 (51.0)  | NR     |

LVEDD, left ventricle end-diastolic diameter; LVESD, left ventricle end-systolic diameter; LVEDV, left ventricle end-diastolic volume; LVESV, left ventricle end-systolic volume; NR, not reported; RV, right ventricular; SPAP, systolic pulmonary artery pressure; TAPSE, tricuspid annular plane systolic excursion; TR, tricuspid regurgitation.

a Data availability from author.

b Index to BSA.

c Standard deviation estimated from Cohen’s formula.

dDefined as TAPSE ≤ 16 mm was significantly associated with increased mortality (HR, 1.72, 95% CI, 1.20–2.48, P = 0.003, I² = 0%) (Supporting Information, Figure S1). Our sensitivity analysis using the leave-one-out-at-a-time approach showed the same direction of the association between mortality and RVD (HR, ranged between 1.73 and 1.86), and so did the association between mortality and moderate–severe TR (HR, ranged between 1.42 and 1.95).

Quality assessment and publication bias

All included studies were of low risk of bias with scores ≥ 7 points on the Newcastle–Ottawa scale (Supporting Information, Table S1). All studies included in the meta-analysis defined their study objective and outcomes, time to follow-up, potential confounders, as well as outlined main study findings. No evidence of significant publication bias was observed in the funnel plots (Figures 4 and 5) and the Egger test (P = 0.15 for RVD, P = 0.48 for moderate–severe TR). Our additional analyses using the ‘trim and fill’ method suggested that hypothetical ‘missing’ studies did not substantially change our pooled estimates for both RVD (HR, 1.74, 95% CI, 1.20–2.48) and severe TR (HR, 1.72, 95% CI, 1.20–2.48).

Discussion

To the best of our knowledge, this is the first meta-analysis investigating the prognostic feature of RV function and TR by echocardiographic assessment in patients with significant FMR receiving MitraClip procedure. The main findings of this study were that an increased risk of mortality was associated with RVD, defined as TAPSE by echocardiography ≤ 16 mm or S/tdi < 10 cm/s, and with moderate to severe TR. It has been well established that RVD and TR have a negative impact on prognosis among patients with cardiovascular diseases,9,10,12,13 but little is known about the prognostic impact of RVD and TR in patients significant FMR receiving MitraClip procedure. Some investigators reported that RVD and TR have been associated with adverse outcomes, but others did not.27,26,31 Because TAPSE and S/tdi ≤ 16 mm or abnormal S/tdi ≤ 10 cm/s, and with moderate to severe TR. It has been shown to correlate with cardiovascular magnetic resonance (CMR)-derived RV ejection fraction,32–34 we pooled the results of observational studies reporting RV function and TR by echocardiography in this meta-analysis. Our objective was to fully understand the implications of RVD and TR in the setting of significant FMR receiving MitraClip procedure. Our meta-analysis suggests that those with RVD (abnormal TAPSE was defined as ≤16 mm or abnormal S/tdi < 10 cm/s) and with moderate–severe TR were more likely to have poor survival outcomes in significant FMR receiving MitraClip procedure, confirming the results of the previous studies. Dini
**Figure 2** The forest plot displays the hazard ratio and 95% confidence intervals (CIs) for difference between patients with and without right ventricular dysfunction. Square markers indicate hazard ratios; horizontal lines, the 95% CIs, with marker size reflecting the statistical weight of the study using random-effects meta-analysis. The diamond marker represents the overall hazard ratio and 95% CI for the outcome of interest.

| Study name    | RVD parameter | Statistics for each study | Hazard ratio and 95% CI |
|---------------|---------------|---------------------------|------------------------|
| Gyetten, 2020 | TAPSE         | 1.260 0.558 2.847 0.566 0.579 |                        |
| Barnehr, 2019 | TAPSE         | 1.480 0.801 2.734 1.232 0.211 |                        |
| Ottersbach, 2018 | STDI    | 4.700 1.116 19.789 2.110 0.035 |                        |
| Ottersbach, 2018 | TAPSE         | 2.840 1.101 7.325 2.159 0.031 |                        |
| Keneko, 2016  | TAPSE         | 1.975 1.026 3.803 2.035 0.042 |                        |
| Giannini, 2016 | STDI         | 1.750 1.208 2.353 2.960 0.003 |                        |
|               |               | 1.791 1.388 2.312 4.480 0.000 |                        |

RVD better RVD worse

**Figure 3** The forest plot displays the hazard ratio and 95% confidence intervals (CIs) for difference between patients with and without moderate–severe tricuspid regurgitation. Square markers indicate hazard ratios; horizontal lines, the 95% CIs, with marker size reflecting the statistical weight of the study using random-effects meta-analysis. The diamond marker represents the overall hazard ratio and 95% CI for the outcome of interest.

| Study name  | Statistics for each study | Hazard ratio and 95% CI |
|-------------|---------------------------|------------------------|
| Gyetten, 2020 | 1.610 0.747 3.468 1.216 0.224 |                        |
| Hahn, 2020   | 0.980 0.520 1.848 -0.062 0.950 |                        |
| Barnehr, 2019 | 2.140 1.180 3.881 2.505 0.012 |                        |
| Ottersbach, 2018 | 1.180 0.342 4.073 0.262 0.793 |                        |
| Ohno, 2014   | 2.670 1.076 6.625 2.118 0.034 |                        |
|              | 1.609 1.113 2.326 2.328 0.011 |                        |

Moderate-Severe TR better Moderate-Severe TR worse

**Figure 4** Funnel plot of publications included in the meta-analysis for right ventricular dysfunction.

**Figure 5** Funnel plot of publications included in the meta-analysis for tricuspid regurgitation.

ESC Heart Failure 2021; 8: 4988–4996
DOI: 10.1002/ehf2.13558
et al. demonstrated that overall survival was greater with TAPSE ≥ 16 mm (82%) when compared with TAPSE <16 mm (42%) at follow up of 36 months (P < 0.001). Importantly, RVD was a significant predictor of all-cause mortality even after adjusting for important confounding factors or covariates (HR, 2.64; 95% CI, 1.28–5.47, P = 0.009). Similarly, Giannini and colleagues revealed that RVD assessed by S′TDI was an independent predictor of cardiovascular mortality in significant FMR. In addition to the association between RVD and mortality, moderate–severe TR has been demonstrated to be associated with adverse prognosis in significant FMR. Calafiore et al. demonstrated, in a propensity score analysis of functional TR that was graded as moderate-or-severe, when left untreated, both midterm survival and functional status were impaired. In our meta-analysis, RVD and moderate–severe TR at baseline posed an increased risk of poor prognosis among patients undergoing MitraClip procedure. RVD is a result of pressure overload or volume overload, or a combination of both, and serves as a common pathway in the progression of congestive heart failure. Additionally, RVD and the severity of TR associated with maladaptive RV remodelling with cardiac myocyte loss and myocardial fibrosis, reducing the possibility of RV functional recovery after intervention of FMR and impacting survival. Therefore, consideration of RV function and the severity of TR could identify FMR patients who may benefit from early intervention before decompensated RV function presents. As also discussed in Introduction section, differences in the results between the COAPT and MITRA-FR studies may lead to underscoring the importance of appropriate patient selection prior to intervention. RV function plays an incremental role in determining survival outcomes of patients with FMR, and this factor is important for candidate selection for patients undergoing MitraClip procedure. RVD confers worse outcomes in significant FMR may be explained by (i) RVD with pressure overload, in the setting of ventricular interdependence, may compromise left ventricular function; (ii) RVD may be unable to maintain the forward output required to maintain adequate left ventricular preload; (iii) the presence of RVD in patients with a history of preexisting cardiac disease is a significant predictor of SCD irrespective of left ventricular ejection fraction. In light of the differing outcomes from MITRA-FR and COAPT trials, an additive value of RVD indices for risk stratification in this population deserves further investigation. Early recognition of RVD by using the index of RV longitudinal contraction (TAPSE) may also be invaluable in planning and timing of intervention for prevention or delay of irreversible RVD. Thus, a deeper investigation into the prognostication of RVD in patients with moderate-to-severe FMR may have both clinical significance and therapeutic implications. Importantly, FMR patients with RVD and/or moderate and severe TR seemed to benefit less frequently from MitraClip procedure, and randomized controlled trials are necessary to provide further insight into these parameters and their roles in identifying patients that are most likely to benefit.

**Study limitations**

First, all of the eligible studies in this meta-analysis were observational with variations in the inclusion criteria, so that heterogeneity is more likely to be present. However, we tried to minimize the bias by carefully selecting studies with low risk of bias, reflected by high scores on the Newcastle–Ottawa scale. The heterogeneity assessed using Cochrane’s Q test and the I² statistic among included studies was not significant, suggesting the limitation did not greatly impact our conclusion. Second, to minimize the risk of false positives in association of RVD and TR with outcomes, we only included studies that adjusted for confounders in multivariable survival analysis. Third, atrial FMR has been under-recognized until recently as a cause of functional MR. Nevertheless, given that included studies are not differentiated between atrial and ventricular FMR in this analysis, we are not able to assess the difference in prognostic impact of right ventricular function and tricuspid regurgitation in these two entities of FMR. Further studies need to be conducted to assess the difference between these two entities. Additionally, haemodynamics of the right ventricle and pulmonary circulation are very crucial components in FMR and should be studied to assess its importance on the clinical outcome. Finally, although our data demonstrated the prognostication of RVD and moderate–severe TR in FMR patients undergoing mitral clip procedure, future studies are still needed to elucidate its role in patient selection.

**Conclusions**

This meta-analysis demonstrates the prognostic importance of RVD and TR grade in predicting all-cause mortality in patients with significant FMR. RV function and TR parameters may therefore be useful in the risk stratification of patients with significant FMR undergoing MitraClip procedure.

**Conflict of interest**

The authors have no conflicts of interest to declare.

**Supporting information**

Additional supporting information may be found online in the Supporting Information section at the end of the article.
Figure 5.1. The forest plot displays the hazard ratio and 95% confidence intervals (CIs) for difference between patients with and without right ventricular dysfunction using TAPSE. Square markers indicate hazard ratios; horizontal lines, the 95% CIs, with marker size reflecting the statistical weight of the study using random-effects meta-analysis. The diamond marker represents the overall hazard ratio and 95% CI for the outcome of interest.

Table S1. Newcastle-Ottawa scale for assessment of quality of included cohort studies. Each asterisk represents fulfilment of the acceptable criteria within each subsection.

References

1. Bursi F, Enriquez-Sarano M, Nkomo VT, Jacobsen SJ, Weston SA, Mevcuden RA, Roger VL. Heart failure and death after myocardial infarction in the community: the emerging role of mitral regurgitation. Circulation 2005; 111: 295–301. https://doi.org/10.1161/01.循.000015097.30779.04
2. Koelling TM, Aaronson KD, Cody RJ, Bach DS, Armstrong WF. Prognostic significance of mitral regurgitation and tricuspid regurgitation in patients with left ventricular systolic dysfunction. Am Heart J 2002; 144: 524–529. https://doi.org/10.1067/mhj.2002.123575
3. Cioffi G, Tarantini L, De Fos S, Pulignano G, Del Sindaco D, Stefennelli C, Di Lenarda A, Opasich C. Functional mitral regurgitation predicts 1-year mortality in elderly patients with systolic chronic heart failure. Eur J Heart Fail 2005; 7: 1112–1117. https://doi.org/10.1016/j.ejheart.2005.01.016
4. Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, Whisenant B, Grayburn PA, Rinaldi M, Kapadia SR, Rajagopal V, Sarembock IB, Brieke A, Marx SO, Cohen DJ, Weissman NJ, Mack MJ, Investigators C. Transcatheter mitral-valve repair in patients with heart failure. New Eng J Med 2018; 379: 2297–2311. https://doi.org/10.1056/NEJMoai1805374
5. Obadia JF, Messika-Zeitoun D, Leurent G, Jung B, Bonnet G, Pirio N, Lefevre T, Piot C, Rouleau F, Carrie D, Nejjar M, Ohlmann P, Leclercq L, Saint Etienne C, Teiger E, Leroux L, Karam N, Michel M, Ohlmann P, Leclercq F, Saint Etienne M, Polge AS, Vannesson C, Topilsky Y, Juthier F, Trochu JN, Enriquez-Sarano M, Bauters C. Right ventricular systolic function in organic mitral regurgitation: impact of biventricular impairment. Circulation 2013; 127: 1597–1608. https://doi.org/10.1161/CIRCULATIONAHA.112.000999
6. Chan V, Burwash IG, Lam BK, Auyeung T, Tran A, Mesana TG, Ruel M. Clinical and echocardiographic impact of functional tricuspid regurgitation repair at the time of mitral valve replacement. Ann Thorac Surg 2009; 88: 1209–1215. https://doi.org/10.1016/j.athoracsur.2009.06.034
7. Antoni ML, Scherptong RW, Atary JZ, Kar S, Lim DS, Mishell JM, Whisenant EE, Schalij MJ, Bax JJ. Prognostic value of right ventricular function in patients after acute myocardial infarction treated with primary percutaneous coronary intervention. Circ Cardiovasc Imaging 2010; 3: 264–271. https://doi.org/10.1161/circimaging.109.914366
8. Mauritz GJ, Kind T, Marcus JT, Bogaard HJ, van de Veerdenok M, Postmus PE, Boonstra A, Westerhof N, Vonk-Noordegraaf A. Progressive changes in right ventricular geometric shortening and long-term survival in pulmonary arterial hypertension. Chest 2012; 141: 935–943. https://doi.org/10.13787/chechest.10-3277
9. Tanaka Y, Hino M, Mizuno K, Gemma A. Evaluation of right ventricular function in patients with COPD. Respir Care 2013; 58: 816–823. https://doi.org/10.4187/respcare.01856
10. Chorin E, Rozenbaum Z, Topilsky Y, Boersma E, Holman ER, van der Wall EE, Schalij MJ, Bax JJ. Predictive value of right ventricular function in patients with left ventricular systolic dysfunction. Circ Arrhythm Electrophysiol 2018; 11: e006091. https://doi.org/10.1161/CIRCARRHYTHM.117.006091
11. A Clinical Evaluation of the Safety and Effectiveness of the MitraClip System in the Treatment of Clinically Significant Functional Mitral Regurgitation (Re-shape-HF2) (ClinicalTrials.gov website). Available at: https://clinicaltrials.gov/ct2/show/NCT0244338. Accessed July 10, 2020.
12. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS medicine 2009; 6: e1000097. https://doi.org/10.1371/journal.pmed.1000097
13. Lefebvre C, Glanville J, Briscoe S, Littlewood A, Marshall C, Metzendorf M-I, Noel-Storr A, Rader TSF, Thomas JWL. Chapter 4: Searching for and selecting studies. In: Higgins JPT, Thomas JA, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from https://www.training.cochrane.org/handbook
14. Gyoten T, Messroghli D, Schenk S, Rochor K, Grimmig O, Just S, Fritzsche D. Impact of preinterventional tricuspid regurgitation on outcome of MitraClip therapy in patients with severely reduced ejection fraction. Open Heart 2020; 7: e001203. https://doi.org/10.1136/openhrt-2019-001203
15. Bannehr M, Kuhn U, Okamoto M, Kaneko H, Hähnel V, Neuß M, Haase-Fielitz A, Butter C. Post-procedural tricuspid regurgitation predicts long-term survival in patients undergoing percutaneous mitral valve repair. J Cardiol 2019; 74: 524–531. https://doi.org/10.1016/j.jcc.2019.05.009
16. Rudski LG, Lai WW, Afifal J, Hua L, Handschumacher MD, Chandrasekaran K, Solomon SD, Louie EK, Schiller NB. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc
Right Ventricular Dysfunction in Patients With Functional Mitral Regurgitation Undergoing MitraClip. *Am J Cardiol* 2016; **118**: 1717–1722. https://doi.org/10.1016/j.amjcard.2016.08.054

29. Giannini C, Fiorelli F, Colombo A, De Carlo M, Weisz SH, Agricola E, Godino C, Castriota F, Golino P, Petronio AS. Right ventricular evaluation to improve survival outcome in patients with severe functional mitral regurgitation and advanced heart failure undergoing MitraClip therapy. *Int J Cardiol* 2016; **223**: 574–580. https://doi.org/10.1016/j.ijcard.2016.08.189

30. Ohno Y, Attizzani GF, Capodanno D, Cannata S, Dipasqua F, Imme S, Barbanti M, Ministeri M, Caggegi A, Pistritto AM, Chiarama M, Ronsivalle G, Giaquinta S, Parruggio S, Mangiafico S, Scandura S, Tamburino C, Caprannano P, Grasso C. Association of tricuspid regurgitation with clinical and echocardiographic outcomes after percutaneous mitral valve repair with the MitraClip System: 30-day and 12-month follow-up from the GRASP Registry. *Eur Heart J Cardiovasc Imaging* 2014; **15**: 1246–1255. https://doi.org/10.1093/ehjci/jeu114

31. Hahn RT, Ashf F, Weismn NJ, Grayburn P, Kar S, Lim S, Ben-Yehuda O, Shahim B, Chen S, Liu M, Redfors B, Medvedofsky D, Puri R, Kapadia S, Sannino A, Lindenfeld J, Abraham WT, Capranzano P, Grasso C. Impact of tricuspid regurgitation on clinical outcomes: the COAPT trial. *J Am Coll Cardiol* 2020; **76**: 1305–1314. https://doi.org/10.1016/j.jacc.2020.07.035

32. Sato T, Tsuchino I, Ohira H, Oyama-Manabe N, Yamada A, Ito YM, Goto C, Watanabe T, Sakaue S, Nishimura M. Validation study on the accuracy of echocardiographic measurements of right ventricular systolic function in pulmonary hypertension. *J Am Soc Echocardiogr* 2012; **25**: 280–286. https://doi.org/10.1016/j.echo.2011.12.012

33. Sade LE, Gülmez O, Ozzer Y, O zgül E, Agildere M, Müddirisoglu H. Tissue Doppler study of the right ventricle with a multisegmental approach: comparison with cardiac magnetic resonance imaging. *J Am Soc Echocardiogr* 2009; **22**: 361–368. https://doi.org/10.1016/j.echo.2009.01.018

34. Wahl A, Praz F, Schwerzmann M, Bone H, Koestner SC, Hullin R, Schmid JP, Stuber T, Delacréaz E, Hess OM, Meier B, Seiler C. Assessment of right ventricular systolic function: comparison between cardiac magnetic resonance derived ejection fraction and pulsed-wave tissue Doppler imaging of the tricuspid annulus. *Int J Cardiol* 2011; **151**: 58–62. https://doi.org/10.1016/j.ijcard.2010.04.089

35. Dini FL, Fontanive P, Panicucci E, Andreini D, Chella P, De Tommasi SM. Prognostic significance of tricuspid annular motion and plasma NT-proBNP in patients with heart failure and moderate-to-severe functional mitral regurgitation. *Eur J Heart Fail* 2008; **10**: 573–580. https://doi.org/10.1016/j.ejheart.2008.04.003

36. Calafiore AM, Gallina S, Iacò AL, Contini M, Bivona A, Gagliardi M, Bosco P, Di Mauro M. Mitral valve surgery for functional mitral regurgitation: should moderate-or-more tricuspid regurgitation be treated? a propensity score analysis. *Ann Thorac Surgery* 2009; **87**: 698–703. https://doi.org/10.1016/j.athoracsur.2008.11.028

37. Andersen S, Nielsen-Kudsk JE, Von Noordegraaf A, de Man FS. Right Ventricular Fibrosis. *Circulation* 2019; **139**: 269–285. https://doi.org/10.1161/circulationaha.118.035326

38. Voelkel NF, Quaife RA, Leinwand LA, Bartsch RJ, McGoon MD, Meldrum DR, Dupuis J, Long CS, Rubin LJ, Smart PW, Suzuki YJ, Gladwin M, Denholm EM, Gail DB. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. *Circulation* 2006; **114**: 1883–1891. https://doi.org/10.1161/circulationaha.106.632208